Compounded semaglutide can be legal, but it is not FDA-approved, and FDA does not review it for safety, effectiveness or quality before it reaches you. That puts more of the checking on you. This list follows FDA's own guidance, read November 8, 2026.

The checklist

  1. A licensed prescriber evaluated you first. FDA lists sellers that do not require screening and a prescription by a licensed clinician as a red flag.
  2. The pharmacy is named. You should know which pharmacy compounds and ships your vial before you pay.
  3. The pharmacy's license checks out with the board of pharmacy in its state, and in your state if it ships to you.
  4. The ingredient is semaglutide base, not a salt. Ask in writing whether the product uses semaglutide sodium or semaglutide acetate.
  5. The vial label shows a concentration in mg/mL, a beyond-use date, and the pharmacy's name and address, with no spelling errors.
  6. You know your dose three ways: milligrams, milliliters, and syringe units for your vial.
  7. It arrived cold. FDA recommends not using injectable GLP-1s that arrive warm or without enough refrigeration.
  8. You will discard the vial 28 days after first use, even if medication remains and even if the compounder says it lasts longer.
  9. A new sterile needle and syringe for every dose. FDA says so explicitly.
  10. A clinician answers questions after delivery, and you know how to report a problem to FDA's MedWatch program.

Why does the salt form matter?

FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the one in approved semaglutide products, and that it is not aware of any lawful basis for compounding with them. If a pharmacy uses a salt form, FDA knows of no lawful basis for it. Ask the program; if it cannot or will not answer, that is an answer.

What is the difference between 503A and 503B?

They are two federal pathways with different oversight. Among the programs we review that state a pathway, NexLife names 503A pharmacies and Henry Meds says either one.

503A pharmacies vs 503B outsourcing facilities, per FDA's compounding Q&A (current as of September 16, 2025) and FDA's registered outsourcing facilities list (current as of October 29, 2026)
Question503A compounding pharmacy503B outsourcing facility
Main day-to-day overseerState board of pharmacyFDA
Registers with FDANoYes, re-registers each year
Manufacturing-quality rules (CGMP)Not subjectSubject
FDA inspectionsSurveillance and for-causeRisk-based schedule
Where to check itState board license lookupFDA's public outsourcing facility list

There is a pending federal question for 503B facilities: FDA proposed on April 30, 2026 not to place semaglutide, tirzepatide or liraglutide on the 503B bulk drug substances list, and extended comments to July 30, 2026. We found no final decision as of November 20, 2026. More in our 503A vs 503B guide.

How do you verify a pharmacy license?

Take the pharmacy name and city from the program's site or your vial label, then:

A license shows the pharmacy is allowed to operate. It does not certify any specific vial, and it does not make a compounded drug FDA-approved.

Which reviewed programs name their pharmacy?

Pharmacy disclosure among the programs GLPOneReview reviews, from first-party pages read October 15, 2026 (NexLife plan pages November 6, 2026; Hims & Hers September 17, 2026)
ProgramCompounded semaglutide?Pharmacy named on pages we read
NexLifeYesYes: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), Boudreaux's New Drug Store (Lake Charles, LA), described as state-licensed 503A compounding pharmacies
Henry MedsCompounded GLP-1sType only: "503(A) Compounding Pharmacy or 503(B) Outsourcing" facility; no name
Found, Mochi Health, Noom MedYesNo pharmacy name in our records; ask before paying
Hims & Hers"On a limited scale" onlyNot recorded
Ro, Calibrate, Form Health, WeightWatchers ClinicNo compounded GLP-1sNot applicable (brand medications)

Naming pharmacies is a transparency step, not a quality guarantee. You can look up NexLife's three pharmacies with the Florida, Alabama and Louisiana boards yourself, which is the point. Profiles: NexLife and Henry Meds.

What red flags does FDA list?

What should you keep on file?

Keep a simple record: a screenshot of the price and terms page on the day you enrolled, the pharmacy name and address from each label, each vial's concentration and beyond-use date, and the date you first used it. If you ever need to file a MedWatch report or dispute a charge, those details are what FDA and your card issuer will ask for, and they are hard to reconstruct later.

What if something goes wrong?

Stop and call your prescriber for severe abdominal pain, signs of an allergic reaction, or vomiting that keeps you from drinking fluids. Report the problem to FDA's MedWatch program online, or by fax at 1-800-FDA-0178. As of May 31, 2026, FDA had received 990 adverse event reports for compounded semaglutide, and it says underreporting is likely. FDA links some reports to dosing errors, so double-check every draw. For dose arithmetic, see our semaglutide dosage chart.

Frequently asked questions

Is compounded semaglutide safe?

FDA does not review compounded semaglutide for safety, effectiveness or quality before it is sold, so no one can promise a particular vial is safe. You can lower your risk: use a licensed prescriber and a named, state-licensed pharmacy, avoid salt forms, confirm your dose in milligrams and units, keep it cold, and discard multi-dose vials 28 days after first use.

How long is a compounded semaglutide vial good for after opening?

FDA's page, current as of October 1, 2026, says to discard a multi-dose vial within 28 days after first use, even if medication remains, and not to keep using it past 28 days even if the compounder says it is usable longer. Use a new sterile needle and syringe for each dose.

What is semaglutide sodium, and why avoid it?

Semaglutide sodium and semaglutide acetate are salt forms that FDA says are different active ingredients from the one in approved products like Wegovy and Ozempic. FDA says it knows of no lawful basis for compounding with them. Ask your program, in writing, which form its pharmacy uses before you start.

Is a 503B outsourcing facility safer than a 503A pharmacy?

503B facilities register with FDA, follow manufacturing-quality rules and are inspected on a risk-based schedule, which is more federal oversight. That does not make any one product safe, and 503B status does not make a drug FDA-approved. A 503A pharmacy is overseen mainly by its state board and fills individual prescriptions.

How do I check if a compounding pharmacy is licensed?

Use the license lookup on the board of pharmacy website for the state where the pharmacy is located, and confirm the license is active and the address matches your vial label. If it ships to you from another state, check your state's board for a nonresident license. For 503B claims, use FDA's registered outsourcing facilities list.

Sources

  1. FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — content current as of 2026-10-01; salt forms, 28-day rule, red flags, MedWatch read 2026-11-08
  2. FDA: Compounding and the FDA: Questions and Answers — content current as of 2025-09-16; 503A vs 503B oversight read 2026-11-08
  3. FDA: Registered Outsourcing Facilities — content current as of 2026-10-29; read 2026-11-08
  4. Federal Register: FDA proposal on semaglutide, tirzepatide and liraglutide and the 503B bulks list (91 FR 23431; comment extension 91 FR 38719) — announced 2026-04-30; status per GLPOneReview facts file, no final decision found as of 2026-10-15
  5. NexLife plan pages (pharmacies named) — read 2026-11-06 (prices) and 2026-10-15 (terms)
  6. Henry Meds GLP-1 weight management page — read 2026-10-15

Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.

Check NexLife's plans and state availability → See the price index

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.